Skip to main content
Theraclion SA logo

Theraclion SA — Investor Relations & Filings

Ticker · ALTHE ISIN · FR0010120402 LEI · 9695007X7HA7A1GCYD29 PA Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2016-06-08 Regulatory Filings
Country FR France
Listing PA ALTHE

About Theraclion SA

https://www.theraclion.com/?_ga=2.14878…

Theraclion SA is a medical device company specializing in the development and marketing of non-invasive therapeutic solutions using High-Intensity Focused Ultrasound (HIFU). The company's technology, known as echotherapy, provides a non-surgical alternative for tissue ablation. Its flagship product, SONOVEIN®, is a robotic solution for the non-invasive treatment of varicose veins. The system uses external ultrasound beams to ablate the target vein without incisions, catheters, or sedation, allowing for immediate patient recovery. Theraclion also developed ECHOPULSE®, a system for the treatment of thyroid nodules and breast fibroadenomas. The company's core focus is on providing precise, non-invasive treatments that reduce risks and recovery time compared to traditional surgical procedures.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 95% confidence The document is a press release dated June 8, 2016, announcing positive clinical study results regarding Theraclion's Echotherapy technology for breast fibroadenoma treatment. It details efficacy data (90% complete destruction), references a presentation at a German Congress of Senology, and includes quotes from management and the lead researcher. This type of announcement, focusing on clinical trial outcomes and scientific updates, is typically classified as an Investor Presentation (IP) if it were a formal deck, or often falls under general Investor Relations (IR) or Regulatory Filings (RNS) if it's a press release format. Since it is a detailed announcement of scientific/clinical progress aimed at investors and the market, and it is not a formal financial report (10-K, IR), a dividend notice (DIV), or a management discussion (MDA), the most fitting category for a significant, non-financial operational update presented to the public/investors is Investor Presentation (IP), as it functions as an informational update often preceding or supplementing formal reports. However, given the structure is a news release format announcing study results, and it is not a formal presentation deck, it is best categorized as a general Regulatory Filing (RNS) or potentially an Investor Relations (IR) document if IR was an option. Comparing the provided definitions, 'IR' (Interim / Quarterly Report) is too specific to financial statements. 'RNS' (Regulatory Filings) is the best fallback for significant, non-standard announcements. Given the content is highly specific clinical data being released to the market, it functions similarly to an Investor Presentation (IP) but lacks the typical presentation structure. I will classify it as 'RNS' as it is a general regulatory announcement of material information not covered by other specific codes.
2016-06-08 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 95% confidence The document is a press release dated June 8, 2016, announcing positive clinical study results regarding the effectiveness of Theraclion's echotherapy for treating breast fibroadenomas. It details preliminary histology results from a study presented at a German Senology Society congress. This type of announcement, focusing on clinical trial outcomes and scientific data presentation, is typically classified as a general corporate announcement or news release. Since it is not a formal regulatory filing (like 10-K, IR, or ER), nor is it specifically about management changes (MANG), director dealings (DIRS), or dividends (DIV), the most appropriate category is the general Regulatory Filings (RNS) fallback, as it is a significant corporate update released to the public/market, often disseminated via regulatory news services.
2016-06-08 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Earnings Release Classification · 98% confidence The document is a press release dated May 24, 2016, announcing strong clinical adoption and growth in treatment numbers, specifically highlighting performance metrics (+115% growth in treatments) and market potential (Germany, Asia). This content structure—a brief announcement of recent operational/financial highlights without comprehensive financial statements or regulatory form headers (like 10-K or 10-Q)—is characteristic of an Earnings Release (ER). It is not a full Annual Report (10-K), an Interim Report (IR), or a transcript (CT). Since it announces key results immediately, ER is the most appropriate classification. FY 2016
2016-05-24 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Earnings Release Classification · 95% confidence The document is a press release dated May 24, 2016, announcing a significant increase in clinical adoption and treatments performed using Theraclion's echotherapy device, highlighting growth in the German and Asian thyroid markets. It details operational and commercial progress, including treatment statistics and market potential. This type of announcement, focusing on recent operational achievements and business updates outside of mandatory periodic financial filings (like 10-K or IR), is best classified as an Earnings Release (ER) if it were quarterly results, or more generally, a significant business update. Since it focuses on operational metrics and commercial success rather than formal financial statements or a transcript, and it is a direct announcement of performance highlights, 'Earnings Release' (ER) is the closest fit among the options for a performance update, although it is not a formal quarterly earnings report. Given the context of financial reporting, this is a key performance announcement. If it were purely a business update without performance metrics, 'RNS' might apply, but the focus on +115% growth strongly suggests an ER-like announcement. FY 2016
2016-05-24 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
AGM Information Classification · 99% confidence The document is titled "Assemblée générale ordinaire et extraordinaire annuelle de Theraclion" (Annual Ordinary and Extraordinary General Meeting of Theraclion) and explicitly states that resolutions were adopted by shareholders during this meeting held on May 12, 2016. It details the approval of annual accounts, renewal of director mandates, and appointments of new directors (Samuel Levy and Wolfram Eichner). This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2016-05-18 French
Communicated under the obligation to provide permanent information / Other communications
AGM Information Classification · 99% confidence The document explicitly discusses the 'outcome of its combined ordinary and extraordinary shareholders' general meeting' and details the resolutions passed, including director appointments and financial statement approvals. This content directly relates to the proceedings and results of an Annual General Meeting (AGM). Although it announces the results, the document itself is a detailed summary of the meeting's outcome, which aligns best with the AGM-R (AGM Information) category, rather than just a brief announcement of a report (RPA) or a general regulatory filing (RNS). The key phrase is 'Theraclion's combined ordinary and extraordinary shareholders' general meeting' and the subsequent listing of resolutions passed.
2016-05-18 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.